Physician
Emergency Medicine
Dr. Marc R. Salzberg, MD
|
|
Give Review
Doctor Marc R. Salzberg, MD practices Emergency Medicine. He attended New York Medical College. Doctor Marc R. Salzberg, MD is a published doctor. He has 16 papers published. The most current publication "Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study." He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study.
- A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors.
- Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small c...
- Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study.
- An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metasta...
- Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.
- Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung ca...
- Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients.
- A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.
- A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
- Current concepts of treatment strategies in advanced or recurrent ovarian cancer.
- Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
- Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
- An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing.
- Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
Schools
New York Medical College
Doctors Specialties
- Emergency Medicine
Accepted Insurances
Education
-
Virginia Mason Medical Center -
New York Medical College
Drug Facts
| NPI NUMBER | 1104994912 | |
| NPPES Provider LastName | SALZBERG | |
| NPPES Provider FirstName | MARC | |
| NPPES Provider ZIPCode | 117872619 | |
| NPPES Provider State | NY | |
| Specialty Description | Emergency Medicine | |
| Total Claim Count | 11.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1104994912 |
| Last Name Of The Provider | SALZBERG |
| First Name Of The Provider | MARC |
| View All |
Similar Doctors
|
|
Danielle L. Morris
 This Doctor is OpenDoctor Recommended.
|
|
|
Sarah Pagliarulo, PA |
|
|
Dr. Janice G. Moldashel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian B. Lee, MD |
|
|
Dr. Jay H. Reich, MD |
|
|
Dr. John E. Shallat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick M. O'Shaughnessy, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diane Peterman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Franklin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria H. London, MD
This Doctor is OpenDoctor Recommended.
|